The current Chief Financial Officer of Orion Group Jari Karlson has announced that he will step down from his position at Orion as of 30 April 2024 and that he will retire.
President and CEO Liisa Hurme says:
“I would like to warmly thank Jari Karlson for his over 20-year career and contribution as Orion's CFO. In addition, he has previously been responsible for a long time at the management board level also for Orion's Animal Health business. During Jari's time, our company has established its position as an international profit-driven pharmaceutical company with a financial management that has evolved to meet international requirements and investor expectations. His successor will be well placed to take the work forward”.
“It has been a privilege to work for a long time with skilled and nice colleagues in such an interesting and challenging industry as the pharmaceutical industry. Orion is a great company and will be such also in the future," says Jari Karlson.
Liisa Hurme continues:
“I warmly welcome René Lindell to Orion and to our executive board to implement our growth strategy. I believe that René's diverse and international experience in various industries in finance, as well as in strategy and business development will be valuable when he starts working at Orion. I look forward to working with him. "
”I’m honored and thrilled to join Orion’s Executive Management Board as CFO. I hope to contribute to Orion’s continued growth and success in being at the forefront of its field. I’m looking forward to meeting and working with all my new colleagues.”
ANNEX: CV of René Lindell
M.Sc. in Economics (Finance), Hanken School of Economics, 2006
Ph.D. in Tech (Engineering Physics), Aalto University, 2005
Rovio Entertainment Corporation
Chief Financial Officer since 2017–
Member of Rovio’s Leadership team since 2016
Chief Strategy Officer and Strategy and Business development officer, 2014–2017
Strategy Director, 2011–2014
Boston Consulting Group
Management Consultant, 2006–2011
Researcher, Low Temperature Laboratory, 2001–2006
| Liisa Hurme
President and CEO
| Olli Huotari
SVP, Corporate Functions
Liisa Hurme, President and CEO
tel + 358 50 966 2874
Contact person for the media:
Terhi Ormio, Vice President, Communications
tel. + 358 50 966 4646
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.